Outcomes for oligometastatic head and neck cancer treated with stereotactic body radiotherapy: Results from an international multi-institutional consortium

被引：2

作者：

Said, Badr Id ^{[1
]}

Mutsaers, Adam ^{[1
]}

Chen, Hanbo ^{[1
]}

Husain, Zain A. ^{[1
]}

Biswas, Tithi ^{[2
]}

Dagan, Roi ^{[3
]}

Erler, Darby ^{[1
]}

Foote, Matthew ^{[4
]}

Louie, Alexander V. ^{[1
]}

Redmond, Kristin ^{[5
]}

Ricardi, Umberto ^{[6
]}

Sahgal, Arjun ^{[1
]}

Poon, Ian ^{[1
,7
]}

机构：

[1] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Dept Radiat Oncol, Toronto, ON, Canada

[2] Univ Hosp Seidman Canc Ctr, Dept Radiat Oncol, Cleveland, OH USA

[3] Univ Florida, Hlth Proton Therapy Inst, Jacksonville, FL USA

[4] Univ Queensland, Princess Alexandra Hosp, Dept Radiat Oncol, Brisbane, Qld, Australia

[5] Johns Hopkins Univ, Dept Radiat Oncol & Mol Radiat Sci, Sch Med, Baltimore, MD USA

[6] Univ Turin, Dept Oncol, Turin, Italy

[7] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, 2075 Bayview Ave,T2 181, Toronto, ON M4N 3M5, Canada

来源：

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2023年 / 45卷 / 10期

关键词：

oligometastatic; head and neck cancer; radiation oncology; SABR; SBRT; SQUAMOUS-CELL CARCINOMA; RADIATION-THERAPY; PULMONARY METASTASES; TRIAL; LUNG; MULTICENTER; RESECTION; ASTRO;

D O I：

10.1002/hed.27488

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

BackgroundWe report the results of an international multi-institutional cohort of oligometastatic (OMD) head and neck cancer (HNC) patients treated with SBRT. MethodsPatients with OMD HNC (& LE;5 metastases) treated with SBRT between 2008 and 2016 at six institutions were included. Treated metastasis control (TMC), progression-free survival (PFS), and overall survival (OS) were analyzed by multivariable analysis (MVA). ResultsForty-two patients with 84 HNC oligometastases were analyzed. The TMC rate at 1 and 2 years were 80% and 66%, with a median time to recurrence of 10.1 months. The median PFS and OS were 4.7 and 23.3 months. MVA identified a PTV point maximum (BED)10 > 100 Gy as a predictor of improved TMC (HR = 0.31, p = 0.034), and a cumulative PTV > 48 cc as having worse PFS (HR = 2.99, p < 0.001). ConclusionFavorable TMC and OS was observed in OMD HNCs treated with SBRT.

引用

页码：2627 / 2637

页数：11

共 50 条

[1] Outcomes for Oligometastatic Head and Neck Cancer Undergoing SBRT: Results From an International Multi-Institutional Consortium
Husain, Z. A.
Chen, H.
Biswas, T.
Dagan, R.
Erler, D.
Foote, M. C.
Louie, A. V.
Redmond, K. J.
Ricardi, U.
Sahgal, A.
Poon, I.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E370 - E371
[2] Outcomes and Toxicities in Oligometastatic Patients Treated With Stereotactic Body Radiotherapy for Adrenal Gland Metastases: A Multi-Institutional Study
Baydoun, A.
Chen, H.
Poon, I.
Badellino, S.
Dagan, R.
Erler, D.
Foote, M. C.
Louie, A. V.
Redmond, K. J.
Ricardi, U.
Sahgal, A.
Biswas, T.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E474 - E474
[3] Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis
Nicosia, Luca
Franzese, Ciro
Mazzola, Rosario
Franceschini, Davide
Rigo, Michele
D'agostino, Giuseppe
Corradini, Stefanie
Alongi, Filippo
Scorsetti, Marta
[J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (03) : 213 - 221
[4] Outcomes and toxicities in oligometastatic patients treated with stereotactic body radiotherapy for adrenal gland metastases: A multi-institutional retrospective study
Baydoun, A.
Chen, H.
Poon, I
Badellino, S.
Dagan, R.
Erler, D.
Foote, M. C.
Louie, A., V
Redmond, K. J.
Ricardi, U.
Sahgal, A.
Biswas, T.
[J]. CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2022, 33 : 159 - 164
[5] An International Multi-Institutional Pooled Analysis of 1033 Extra-Cranial Oligometastatic Patients Treated with Definitive Stereotactic Body Radiotherapy (SBRT)
Erler, D.
Dagan, R.
Redmond, K. J.
Foote, M. C.
Badellino, S.
Biswas, T.
Louie, A. V.
Ricardi, U.
Sahgal, A.
Poon, I.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E164 - E165
[6] Bone Only Oligometastatic Renal Cell Carcinoma Patients Treated with Stereotactic Body Radiotherapy: A MULTI-Institutional Study
Onal, C.
Guler, O. C.
Hurmuz, P.
Yavas, G.
Tilki, B.
Oymak, E.
Yavas, C.
Ozyigit, G.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E209 - E209
[7] An international multi-institutional planning study for spine stereotactic body radiotherapy
Hiroshi, T.
Furuya, T.
Naoto, S.
Nakayama, M.
Mark, R.
Hao, P. Jun
Thibault, I.
St-Hilaire, J.
Lijun, M.
Pinnaduwage, D.
Sahgal, A.
Katsuyuki, K.
[J]. RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S926 - S926
[8] Stereotactic Body Radiotherapy in Recurrent and Oligometastatic Head and Neck Tumours
Tham, Jodie L. M.
Ng, Sweet Ping
Khor, Richard
Wada, Morikatsu
Gan, Hui
Thai, Alesha A.
Corry, June
Bahig, Houda
Makitie, Antti A.
Nuyts, Sandra
De Bree, Remco
Strojan, Primoz
Ng, Wai Tong
Eisbruch, Avraham
Chow, James C. H.
Ferlito, Alfio
[J]. JOURNAL OF CLINICAL MEDICINE, 2024, 13 (11)
[9] Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study
Onal, Cem
Guler, Ozan Cem
Hurmuz, Pervin
Yavas, Guler
Tilki, Burak
Oymak, Ezgi
Yavas, Cagdas
Ozyigit, Gokhan
[J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2022, 198 (10) : 940 - 948
[10] Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study
Cem Onal
Ozan Cem Guler
Pervin Hurmuz
Guler Yavas
Burak Tilki
Ezgi Oymak
Cagdas Yavas
Gokhan Ozyigit
[J]. Strahlentherapie und Onkologie, 2022, 198 : 940 - 948

← 1 2 3 4 5 →